Part 1

Mar 6, 2017 A good explanation of green teas strengths over other antioxidant rich foods for use in the product Phytofare. Phytofare® has been clinically proven in human studies to provide ten times greater bioavailability, which is the ability of the body to absorb the nutrients, over generic plant extracts. The first product brought to market, Phytofare® catechin complex, is derived from green tea and contains all eight catechins in a highly absorbable biocompatible structure. Where the original product as developed by, Plandaí Biotechnology, focused on selling Phytofare® as an ingredient to manufacturers in the nutraceuticals industry, Plandaí SA will target the pharmaceutical market with a finished product.
Protext’s Acquired Technology
Green tea and type 2 diabetes

Part 2

Mar 7, 2017 Protext CEO discusses its lead product Phytofare® and how green tea catechins (antioxidants) if delivered with greater bioavailability, has significant benefits and advantages over the way traditional green tea is consumed. Phytofare® green tea catechin complex in capsule form taken daily can help aid as a preventative measure as well as help combat metabolic syndrome causes especially for type II Diabetes but also includes wellness benefits in addressing high blood pressure, cholesterol, and weight issues.
Bioavailability of catechins Hu Ming
Bioavailability Final Results – 2nd Arm
Modified copy of Abstract_Nicola coschem
Study report Bioavailabiltiy_ Plandai _June 2015
Coschem NBarnard

Part 3

Mar 29, 2017 Protext Mobility releases video interview w/ CEO discussing Cannabis Biosciences acquisition, science behind Phytofare, cannabis research, and exciting future of TXTM.
Betty Ishida USDA Food Chemistry
Summary of CRS Science, Nov 2012
KC1662 Origine 8 Detailer

Part 4

May 12, 2017 Roger Duffield shares with investors and shareholders more details on TXTM’s progress with medical marijuana license in South Africa.
Letter DOH
QC Manual – Final
Operating Plan – Final
SOP – Final

Part 5

May 13, 2017 Roger Duffield finishing the interview explaining the details on Cannabis Bioscience’s medical marijuana license in South Africa.
Pharmoketics of Cannabinoids
Plandai Letter
Site Master File.Jan 2018

Part 6

Aug 1, 2017 Video Update from 7/26/17 – TXTM CEO Roger Duffield at site location where cannabis operations to take place. Subsequently, all final documents requested by Ministry of Health have been submitted for license issuance

Part 7

Jul 26, 2018 Part 1 of 2, TXTM, Protext Pharma CEO update on medical cannabis license in South Africa.

Part 8

Jul 26, 2018 TXTM, Protext Pharma CEO updates part 2 of 2 on Medical Cannabis License in South Africa.

Part 9 - April 30, 2020

Republic of South Africa Medical Marijuana Dispensaries (RSAMMD) Signs Letter of Intent with USA-based Protext Pharma (TXTM) for Commercialization of Next Generation Live Cannabis and Hemp Extraction Technology
View Publication

Part 10 - May 7, 2020

Republic of South Africa Medical Marijuana Dispensaries (RSAMMD) Announces Successful Testing Results of Proprietary Cannabis Plant Extraction Technology with JV Partner Protext Pharma (TXTM)
View Publication
CoA.Extraction.Samples1.March 2020

Part 11 “Roger Duffield’s Blessing”

Dear: Dylon

I cannot help you anymore with your development work as my health and other challenges are my priority, my research with cannabis stopped 4 years ago when I first became ill and I cannot add to the findings and application submitted to SAPHRA at that time, You have the methodology to produce the liquid phase from which you have to remove the solids, oil and phytonutrient phases.

Dr J has the wherewithal to conduct these experiments and has other supporting equipment such as Super Critical Extract which may play a significant part

I wish you all the best with your investigations

Science is very challenging and especially cannabinoids so you will need to remain focused on the prime objective.

Part 12 - 13 June 2022

View Publication

Part 13 - 17 June 2022

Republic of South Africa Medical Marijuana Dispensaries Acquisitions LLC ( to discuss its recent acquisition of Protext Mobility, inc. (TXTM) at the emerging growth conference Wednesday June 22, 2022 12:30pm est
View Publication

Part 14 - 30 June 2022

RSAMMD Acquisitions LLC and Protext Mobility, Inc. (TXTM) pleased to announce its chairman Dr. Ahmed Jamaloodeen has received the high honor of being appointed as national commodity board chairman of cannabis and all indigenous flora
View Publication

Part 15 - Where Protext Mobility INC - (Protext Pharma) Was Prior to Merger

  1. Current $TXTM Balance sheet
  2. No Operating Cash
  3. No Web Site
  4. Limited Staff
  5. No Permits/No Licenses to legally conduct cannabis tests on Extraction equipment
  6. No Biomass
  7. No Farm Land
  8. No Facilities/Offices
  9. No Equipment/Machinery
  10. No Kettles
  11. No Expertise or Qualifications
  12. No Sales Team
  13. No Marketing Team
  14. No Work has been Conducted on Extraction Equipment before RSAMMD JV
  15. No Rodger Duffield


Part 16 - Where Protext Mobility INC - (Protext Pharma) is Now After Merger with RSAMMDA

What $TXTM was not able to obtain before RSAMMDA Merger highlighting the True Value of the Human CAPITAL in creating ACCESS to the following

  1. Kettle
  2. Farm Land 5000 Hectares
  3. Cannabis/Hemp Permits
  4. Dispensing License
  5. Biomass
  6. Seeds
  7. Intellectual Property
  8. Qualifications
  9. Government
  10. Union
  11. Contacts
  12. Products Development
  13. Products to Market (Local & Export)
  14. Global Distribution
  15. Export Permits
  16. Import Permits to Europe, USA, Caribbean, South America, Australia, Singapore onto the East.
  17. Equates to increase in shareholder value


View Press Release

Bright Future Ahead for $TXTM Global Healing & Humanity as a Whole. #LetsGo #TXTMTribe